Nemvaleukin alfa
Modify Date: 2024-07-17 17:23:38
Nemvaleukin alfa structure
|
Common Name | Nemvaleukin alfa | ||
|---|---|---|---|---|
| CAS Number | 2315268-27-8 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Nemvaleukin alfaNemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer[1][2][3]. |
| Name | Nemvaleukin alfa |
|---|
| Description | Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Nemvaleukin alfa 激活食蟹猴和人类样本的淋巴细胞亚群，EC50s 为 0.45-2.2 nM[2]。 Nemvaleukin alfa (0-100 nM，30 分钟) 诱导人细胞 (HH 细胞) 上的中等亲和力 IL-2R 的激活[3]。 Nemvaleukin alfa (0-100 nM，30 分钟) 在 NK 细胞中诱导 pSTAT5，EC50 为 0.45 nM[3]。 Nemvaleukin alfa (0.5 nM，5 天) 诱导从人外周血中分离的效应淋巴细胞的激活[3]。 |
| In Vivo | Nemvaleukin alfa (6 mg/kg，皮下注射，每 4 天一次) 抑制小鼠 SCLC 肿瘤的生长[1]。 Animal Model: SCLC orthotopic model[1] Dosage: 6 mg/kg Administration: s.c., every 4 days Result: Delayed tumor growth and prolonged survival. Animal Model: Male cynomolgus monkeys (PK Assay)[2] Dosage: 0.3 or 1 mg/kg Administration: i.v. or s.c. Result: Pharmacokinetic profile of Nemvaleukin alfa. Dose Route dose (mg/kg) Cmax (ng/mL) Tmax (h) T1/2 (h) i.v. 0.3 6119 0.083 49.5 s.c. 0.3 549 8 61.9 s.c. 1 1035 8 37.3 |
| References |
| No Any Chemical & Physical Properties |